Advanced Tools for Cancer Biomarker Discovery and Validation
As a gene-centric company, OriGene has developed new technologies and products for cancer biomarker discovery and validation
Tissue Biorepository
- More than 140,000 tissues from U.S. Hospitals
- Collected under strict IRB practices
- Annotated with clinical data
TissueScan
- mRNA expression profiling via qPCRs
- Panels of normalized cDNA prepared from tumor tissues
- Including breast, colon, lung, ovarian and prostate
qPCR Primer Panels
- 21 pre-designed key cancer pathways
- qPCR screening-ready formats
- Custom panels available
